Pharmamark Nutrition commercializes CSIRO’s IntEncap™ microencapsulation technology to load lipid and bioactive nutrients from marine, algal, vegetable and fungal oils into shelf-stable spray-dried powders. The IntEncap process uses a flexible protein and carbohydrate base with an emulsion film to protect sensitive nutrients, enabling customised dry‑blend infant formula and other human food formulations. Pharmamark is focused primarily on the omega-3 DHA infant formula market in Asia and Oceania and has targeted the US$62.5 billion global baby milk formula market. Funds from the recent investment will be used to develop CSIRO’s microencapsulation technology and to complete a spray dryer facility in Thailand to microencapsulate oils including OPO, anhydrous milk fat and PUFA oils. The executive team includes CEO Guy Drummond, who has long been associated with the CSIRO technology, and personnel experienced in infant formula, manufacturing and omega fatty acids. The article does not disclose revenues or other operating metrics.

Total raised

$6M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2021